Core Laboratories Inc. /DE/
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $526.5M | $523.8M | $509.8M | $489.7M | $470.3M |
| Cost of revenue | $417.6M | $420.5M | $400.0M | $393.7M | — |
| Operating income | $56.5M | $58.6M | $54.6M | $41.5M | $45.3M |
| Interest expense | $10.6M | $12.4M | $13.4M | $11.6M | $9.2M |
| Pretax income | $45.9M | $46.2M | $41.2M | $30.0M | $36.1M |
| Income tax expense | $15.5M | $14.0M | $4.2M | $10.3M | $15.9M |
| Net income | $29.7M | $31.4M | $36.7M | $19.5M | $19.7M |
| Balance Sheet | |||||
| Cash and equivalents | $22.7M | $19.2M | $15.1M | $15.4M | — |
| Current assets | $214.7M | $221.3M | $223.1M | $211.7M | — |
| Total assets | $584.0M | $585.1M | $586.4M | $578.4M | $580.9M |
| Current liabilities | $106.0M | $102.4M | $88.1M | $103.1M | — |
| Stockholders' equity | $266.0M | $246.6M | $224.8M | $184.3M | $161.0M |
| Cash Flow Statement | |||||
| Cash from operations | $37.0M | $56.4M | $24.8M | $25.0M | $36.6M |
| Depreciation and amortization | $14.6M | $15.0M | $15.8M | $17.2M | $18.5M |
| Stock-based compensation | $7.1M | $3.8M | $14.0M | $7.8M | $19.1M |
| Capital expenditure | $11.2M | $11.9M | $10.6M | $10.2M | $13.5M |
| Free cash flow | $25.8M | $44.5M | $14.2M | $14.7M | $23.0M |
| Dividends paid | $1.9M | $1.9M | $1.9M | $1.9M | $1.8M |
| Share repurchases | $12.4M | $5.3M | $2.2M | $3.9M | $8.3M |
| Impairments | $34,000 | $1.1M | $1.1M | $0 | $0 |
Shares outstanding 46.1M · Free float 69.6%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.